Suppr超能文献

外用过氧化苯甲酰/克林霉素与外用克林霉素及赋形剂在减少痤疮丙酸杆菌方面的效果比较

Effect of topical benzoyl peroxide/clindamycin versus topical clindamycin and vehicle in the reduction of Propionibacterium acnes.

作者信息

Leyden James J

机构信息

Department of Dermatology, University of Pennsylvania School of Medicine and Hospital of the University of Pennsylvania, Philadelphia 19104-4283, USA.

出版信息

Cutis. 2002 Jun;69(6):475-80.

Abstract

Propionibacterium acnes is one of the primary factors involved in the pathogenesis of acne vulgaris; proliferation of this bacteria is present in all patients with inflammatory lesions. Combination topical therapy with agents that have different but complementary antimicrobial mechanisms of action has the potential to increase efficacy and to prevent the emergence of resistant organisms. The onset of action and effectiveness of 3 topical preparations (benzoyl peroxide 5%/clindamycin phosphate 1% gel, clindamycin phosphate 1% solution, and vehicle gel) in reducing P acnes were compared in a randomized, open-label, evaluator-blinded, comparative trial involving 60 healthy volunteers who were free of acne but had high levels of facial P acnes. Treatment with benzoyl peroxide 5%/clindamycin phosphate 1% gel significantly (P<.001) reduced P acnes levels by >1 log10/cm2 from baseline (91% inhibition) 24 hours after application. Progressive declines were observed throughout the 2-week study period, with a 3 log10/cm2 reduction (99.9% inhibition) from baseline in P acnes at the end of the 2-week treatment period. In contrast, significant (P<.05) reductions from baseline in P acnes levels following treatment with clindamycin phosphate 1% solution were only observed at the last assessment period (2 weeks), with an average reduction of 0.64 log10/cm2 (77% inhibition). Patients receiving vehicle gel had no measurable reductions in P acnes from baseline. These results demonstrate that topical benzoyl peroxide 5%/clindamycin phosphate 1% gel produces rapid and clinically relevant reductions in P acnes greater than those produced by single-agent therapy. This activity is likely responsible for the quick onset of clinical efficacy produced by this combination regimen.

摘要

痤疮丙酸杆菌是寻常痤疮发病机制中的主要因素之一;所有有炎症性皮损的患者均存在这种细菌的增殖。联合使用具有不同但互补抗菌作用机制的药物进行局部治疗,有可能提高疗效并防止耐药菌的出现。在一项随机、开放标签、评估者盲法的对照试验中,比较了3种局部制剂(5%过氧化苯甲酰/1%克林霉素磷酸酯凝胶、1%克林霉素磷酸酯溶液和赋形剂凝胶)在减少痤疮丙酸杆菌方面的起效时间和效果,该试验纳入了60名无痤疮但面部痤疮丙酸杆菌水平较高的健康志愿者。使用5%过氧化苯甲酰/1%克林霉素磷酸酯凝胶治疗后24小时,痤疮丙酸杆菌水平较基线显著降低(P<0.001),降低幅度>1 log10/cm²(抑制率91%)。在整个2周的研究期间观察到痤疮丙酸杆菌水平逐渐下降,在2周治疗期结束时,痤疮丙酸杆菌较基线降低了3 log10/cm²(抑制率99.9%)。相比之下,仅在最后评估期(2周)观察到1%克林霉素磷酸酯溶液治疗后痤疮丙酸杆菌水平较基线有显著降低(P<0.05),平均降低0.64 log10/cm²(抑制率77%)。接受赋形剂凝胶治疗的患者痤疮丙酸杆菌水平与基线相比没有可测量的降低。这些结果表明,局部使用5%过氧化苯甲酰/1%克林霉素磷酸酯凝胶能使痤疮丙酸杆菌快速且在临床上显著降低,降幅大于单药治疗。这种活性可能是该联合治疗方案临床疗效起效快的原因。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验